“I don’t see how it is going to end up being good for a pharma company,” said Ronny Gal, a pharmaceutical analyst for the Wall Street firm Bernstein. “Once you become a political opinion, that’s not great.”
If you’re listening to Trump on Tucker praising Regeneron yet again, read on how he’s putting the company in a tough spot
Pharmaceutical companies often pay handsomely for celebrity endorsements, but this patient testimonial was like no other.